About 30M Genomics
30M Genomics is a company based in Eluru (India) founded in 2019 by Benet Bosco Dhas, Pavani Pavuluri, and Yaswanth Reddy. 30M Genomics has raised $131.67 thousand across 4 funding rounds from investors including AIC-CCMB, JioGenNext and Amey Mashelkar. 30M Genomics offers products and services including Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits. 30M Genomics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Eluru, India
- Founders Benet Bosco Dhas, Pavani Pavuluri, Yaswanth Reddy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 30M Genomics Private Limited
- Date of Incorporation 18 Jul, 2019
- Jurisdiction West Godavari District, Andhra Pradesh, India
-
Annual Revenue
$33.12 K (USD)584.4as on Mar 31, 2022
-
Net Profit
-$4.57 K (USD)-45.96as on Mar 31, 2022
-
EBITDA
-$32.05 K (USD)-316.13as on Mar 31, 2022
-
Total Equity Funding
$131.67 K (USD)
in 4 rounds
-
Latest Funding Round
$58.17 K (USD), Seed
Jan 03, 2025
-
Investors
AIC-CCMB
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 30M Genomics
30M Genomics offers a comprehensive portfolio of products and services, including Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits.
Saliva-based tests for personalized medicine and disease risk.
AI-driven reports for accurate drug dosing recommendations.
PCR-based kits for genetic disease and infectious analysis.
Ready-to-use kits for rapid genomics applications.
Kits for efficient DNA extraction and analysis.
Funding Insights of 30M Genomics
30M Genomics has successfully raised a total of $131.67K across 4 strategic funding rounds. The most recent funding activity was a Seed round of $58.17 thousand completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 30M Genomics
30M Genomics has secured backing from 6 investors, including angel and venture fund investors. Prominent investors backing the company include AIC-CCMB, JioGenNext and Amey Mashelkar.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector agnostic startup incubator
|
Locked | Locked | Locked | |
|
Startup engagement platform providing market access and guidance within the Reliance ecosystem.
|
Locked | Locked | Locked | |
|
Startups are incubated at Venture Center, backed by CSIR.
|
Locked | Locked | Locked |
Investor details for 30M Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 30M Genomics
Investment portfolio details for 30M Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 30M Genomics
Detailed financials for 30M Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
30M Genomics Comparisons
Peer comparison for 30M Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 30M Genomics
30M Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of 30M Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 30M Genomics
Complete news archive for 30M Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 30M Genomics
30M Genomics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
30M Genomics is headquartered in Eluru, India. It is registered at Eluru, Andhra Pradesh, India.
Benet Bosco Dhas is the current CEO of 30M Genomics. They have also founded this company.
30M Genomics is a funded company, having raised a total of $131.67K across 4 funding rounds to date.
Annual revenue of 30M Genomics is $33.12K as on Mar 31, 2022.
30M Genomics was established in 2019 in Eluru, India, within the biotechnology sector focused on precision medicine. Platforms such as PGx War have been created to personalize coumarin anticoagulant dosages for cardiovascular patients. EmerSep, a bedside tool for sepsis diagnostics, has also been developed to support clinical decision-making. Operations center on genomic applications for drug personalization and rapid diagnostics in healthcare settings.
30M Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
30M Genomics offers Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits.
30M Genomics has 6 investors. Key investors include AIC-CCMB, JioGenNext, Amey Mashelkar, Ra Mashelkar, and India DeepTech.
The valuation of 30M Genomics is $748.09K as of Nov 2021.